Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study
Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.1827
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2013
Authors
Publisher
Elsevier BV